ZTS

Zoetis Inc. operates in the healthcare sector, within the biotechnology and pharmaceutical industry for veterinary use, focusing on the development, manufacturing and commercialization of medicines, vaccines and diagnostic solutions for animal health.

The company originated from Pfizer’s veterinary operations and later became an independent entity dedicated exclusively to the animal health segment.

Its creation was driven by the need to enhance specialization and efficiency in solutions for livestock and companion animals, amid global growth in veterinary care, food safety and animal welfare demands.

The company’s portfolio includes vaccines, antiparasitics, antibiotics, anti-inflammatories, diagnostic tools, laboratory tests, reproductive solutions and digital monitoring technologies. These solutions serve livestock production, poultry, swine, equine, companion animals and aquaculture.

Zoetis has a global presence in more than 45 countries, with significant operations in the United States, Europe, Brazil, China and emerging agribusiness markets. Its products are supplied to veterinary clinics, distributors, livestock producers, pet retailers, veterinary hospitals and agribusiness organizations.

Key market factors include the expansion of the companion animal segment, increased global protein demand, advances in biotechnology, international sanitary regulations and competition from companies such as Elanco, Boehringer Ingelheim and Merck Animal Health.

The operational structure includes global research centers, manufacturing sites for pharmaceuticals and vaccines, diagnostic laboratories, logistics hubs and regional support units. The company employs specialized scientists, veterinarians and engineering teams, ensuring continuous innovation in products and technologies.

Zoetis Inc. shares are traded on the New York Stock Exchange (NYSE) under the ticker ZTS.

History and Foundation of Zoetis Inc.

Zoetis Inc. was officially formed in 2012 in the United States, following the spin-off of Pfizer’s animal health division. However, its origins date back to the early 20th century, when Pfizer began conducting research related to animal health, building decades of expertise in the veterinary sector.

In its early years as an independent company, Zoetis focused on strengthening operational autonomy, integrating its product portfolio and expanding its global footprint. In 2013, the company conducted its initial public offering (IPO) on the NYSE, marking one of the largest healthcare IPOs of that period.

Throughout the following decade, Zoetis expanded through strategic acquisitions in diagnostics, digital technologies and advanced therapies for companion animals, including companies specializing in veterinary diagnostics and behavioral monitoring platforms.

Between 2020 and 2024, the company faced challenges stemming from the COVID-19 pandemic, which affected supply chains and the demand for veterinary services.

During this period, Zoetis reinforced its manufacturing capacity, invested in automation and expanded its offering of innovative therapies, including dermatological treatments and recombinant biotechnology solutions.

The company continues to strengthen its portfolio and expand its presence in strategic markets, maintaining its position as a global leader in animal health.

Additional Information

The Company Zoetis Inc. (United States), is listed on NYSE with a market value of $ 56.41 Billions, having an equity of $ 3.33 Billions.

With a total of 11.300 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.

In the last 12 months the Company had a revenue of $ 9.47 Billions, which generated a profit in the amount of $ 2.67 Billions.

As for its main indicators, the Company has a P/E ratio of 21.10, a P/BV ratio of 16.93 and in the last 12 months the dividend yield of ZTS was at 1.55%.

The Company is traded internationally through the ticker ZTS.